Friday, November 13, 2026

Dollar Hits 2022 Lows as Euro Surges 14%, Pound Gains 7% Amid Fed Transition Fears

The US dollar fell to its lowest level since 2022, with the Euro up 14% and British Pound gaining 7% in 2025. Market uncertainty ahead of Jerome Powell's June 2026 Fed chair transition and progress on Iran-US nuclear talks drove the weakness. Analysts warn GBP could reverse below $1.30 as the UK Budget and Fed leadership change approach.

Dollar Hits 2022 Lows as Euro Surges 14%, Pound Gains 7% Amid Fed Transition Fears
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The US dollar slumped to its weakest level since 2022, pressured by mounting uncertainty over the Federal Reserve's leadership transition and shifting geopolitical dynamics. The Euro climbed 14% against the greenback in 2025, while the British Pound posted a 7% gain.

Market anxiety centers on Jerome Powell's scheduled departure as Fed chair in June 2026. Investors face limited visibility on monetary policy direction as the transition approaches, weakening dollar demand. The currency decline accelerated as Iran-US nuclear deal negotiations advanced, reducing geopolitical risk premiums that previously supported the dollar.

Currency traders rotated into non-dollar assets throughout 2025. The Euro strengthened as European Central Bank policy diverged from Fed expectations. Sterling rose despite UK domestic pressures, with the Pound trading at $1.3086 after briefly touching higher levels earlier this year.

Jordan Rochester at Mizuho Bank warned the Pound's rally faces limits. "GBP could fall below $1.30" as the UK Budget scheduled for November 26 approaches, he said. Chancellor Rachel Reeves plans additional tax increases to address fiscal gaps, potentially weighing on Sterling.

Simon Phillips, Managing Director at No1 Currency, noted mounting pressure on GBP despite year-to-date gains. UK 30-year gilt yields climbed 4 basis points to 5.21%, the highest since August 1998. Two-year and 10-year yields also rose as inflation concerns persisted.

The Pound fell 0.4% to €1.13 against the Euro, hitting its lowest since April 2023. Against the dollar, Sterling dropped 0.5% in recent trading. Currency analysts see the Fed leadership transition as a key turning point for dollar direction through 2026.

Neil Wilson at Saxo Markets highlighted fiscal instability risks across major economies. Market participants positioned for continued dollar weakness, though forecasts suggest the decline may be nearing limits. The Euro-dollar and Cable (GBP/USD) pairs emerged as primary beneficiaries of greenback selling.

Traders watch Fed communications and UK fiscal policy for the next catalyst. The dollar's decline opened opportunities in currency pairs, but analysts caution against chasing trends as technical levels approach potential reversal zones.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com